Biointron has launched "Spotlight on Antibodies", a monthly podcast diving deep into the world of antibody innovation. Listen to our first episode on Podbean, Spotify, Apple, or Amazon Music!
Spotlight on Antibodies by Biointron is your go-to monthly podcast exploring the latest trends, breakthroughs, and challenges in the antibody industry. From cutting-edge technologies like high-throughput antibody discovery to insights on market shifts and regulatory updates, we bring you expert perspectives and actionable knowledge to stay ahead in this competitive field. Whether you’re a biotech professional, researcher, or industry enthusiast, this podcast offers a perfect blend of education and industry updates, helping you stay informed and inspired to innovate.
Spotify: https://open.spotify.com/show/5PjDa21vqVr14zVarbw8B7
Apple Podcasts: https://podcasts.apple.com/us/podcast/spotlight-on-antibodies-episode-1-january-1-31-2025/id1792008646?i=1000685033636ee
Amazon Podcasts: https://music.amazon.com/podcasts/4649eb8f-ef17-4b1d-ae19-0c5dbf766fbf/spotlight-on-antibodies
PodBean: https://biointronusa.podbean.com/
DOI: 10.3389/fbioe.2022.856049Antibodies have become essential tools for the diagnosis and treatment of numerous human diseases. However, non-human antibodies, such as those derived from murine sources, often provoke human anti-mouse antibody (HAMA) responses. This immunogenicity leads to rapid clea
In therapeutic antibody development, achieving high-affinity antigen binding is central to improving drug efficacy, durability, and safety.Biointron’s High-Throughput Fully Human Antibody Discovery service is designed to meet this need by integrating advanced screening and engineering technol
I. Introduction to Hybridoma TechnologyHybridoma technology, developed by Köhler and Milstein in 1975, is a foundational method for producing monoclonal antibodies (mAbs). The approach involves fusing antibody-producing B lymphocytes with immortal myeloma cells to form hybridoma cells. These hybrid
Introduction to Monoclonal Antibody Discovery Monoclonal antibodies (mAbs) are one of the most successful classes of biologic drugs on the global pharmaceutical market. Since the approval of Orthoclone OKT3 in 1986, over 100 mAbs have been approved by the U.S. FDA for indications incl